The treatment of differentiated thyroid carcinoma (DTC) is currently based on initial staging systems that predict mortality. Recurrence, however, is a much larger problem than mortality in DTC. Tuttle et al. have tested the new American Thyroid Association recurrence risk staging system and found that truly accurate staging requires continuous prognostic re-evaluation according to treatment results.
- Frederik A. Verburg
- Christoph Reiners